{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', '7.2.3.', 'Vital Signs, Physical Examination, and ECG', 'Assessment of vital signs (supine blood pressure, heart rate, and body temperature) physical', 'examination and ECG will be performed at the time points indicated in the general SoA', '(Table 1) (pre-dose at dosing days).', 'Supine blood pressure and heart rate will be measured using standard equipment after', '10 minutes rest on a bed.', 'It is recommended that the method used to measure body temperature at Screening is', 'maintained throughout the trial for each patient.', 'A physical examination will include at a minimum an assessment of general appearance,', 'skin, lymph nodes, musculoskeletal/extremities, abdomen, cardiovascular, respiratory, and', 'neurological system.', 'Height will be measured at Screening only and weight will be measured at Screening and at', 'the EoS/ED visit. Weight measurement can be repeated at any visit when there is an obvious', 'weight change compared to the last weight assessment. For the assessment of height and', 'weight, patients will be required to remove their shoes and wear light indoor clothing for', 'these measurements.', 'A 12-lead ECG will be recorded locally as per local regulations in the supine position after', 'the patient has rested in this position for at least 10 minutes. The assessments on heart rate,', 'PR, QT and QRS intervals will be read centrally.', '7.2.4.', 'Suicidality Assessment', 'As is recommended for trials involving a biological product for a neurological indication, a', 'prospective assessment for suicidal ideation and behavior will be included in this clinical', 'trial.', 'This so-called suicidality assessment will be conducted by specifically asking the following', 'question, derived from the PHQ-9:', '\"Over the last 2 weeks, how often have you been bothered by thoughts that you would', 'be better off dead, or of hurting yourself in some way?\"', 'The patient will be asked this question at each visit and the response documented. Response', 'options as per the PHQ-9 are limited to the following: \"not at all\", \"several days\", \"more', 'than half the days\" or \"nearly every day\".', 'This specific question was selected for the reported significant linear relationship between', 'the item 9 score of the PHQ-9 and the risk of subsequent suicide attempt (Simon, Rutter et al.', '2013).', 'argenx BVBA', 'Confidential', 'Page 85 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', '7.2.5.', 'Medical and Surgical History', 'Clinically significant findings and pre-existing conditions present in a patient prior to', 'Screening must be reported on the relevant medical history/current medical conditions page', 'of the eCRF.', 'Information should be provided on medical and surgical history and concomitant medical', 'conditions specifying those ongoing at Screening.', '7.2.6.', 'Data Safety Monitoring Board (DSMB)', 'The Sponsor will appoint a DSMB consisting of an independent group of clinical experts,', 'who are not participating in the trial. They will be supplemented by an independent', 'statistician. The objective of the DSMB will be to review all unblinded safety data (including', 'the overall number of patients treated up to that point, rates, and patient-level details) and', 'determine if there is an imbalance in the treatment arms with respect to these events, based', 'on clinical judgment of the DSMB. Fixed meetings will be scheduled based on the', 'recruitment rate into the trial, and incidence of (S)AF In addition, ad hoc meetings can be', 'requested at any time during the trial by either the Sponsor or the DSMB. The DSMB will', 'advise the Sponsor concerning continuation, modification or termination of the trial after', 'every meeting.', 'The composition, objectives, and role and responsibilities of the independent DSMB will be', 'described in a DSMB charter, agreed with the DSMB members and Sponsor. The DSMB', 'charter will also define and document the content of the safety summaries, and general', 'procedures (including communications).', '7.2.7.', 'Visit Reminder/Subject ID Card', 'Patients must be provided with the address and telephone number of the main contact for', 'information about the clinical trial. The Investigator must therefore provide a \"Visit', 'Reminder/Subject ID Card\" to each patient. In an emergency situation this card serves to', 'inform the responsible attending physician that the patient is in a clinical trial and that', 'relevant information may be obtained by contacting the Investigator. Patients must be', 'instructed to keep the card in their possession at all times.', '7.3.', 'Pharmacokinetics (PK)', 'Blood samples for PK will be collected from each patient as presented in Table 1.', 'Concentrations of ARGX-113 will be determined using a validated assay. The actual date', 'and time of collection of the blood sample will be recorded in the relevant section of the', 'eCRF.', 'argenx BVBA', 'Confidential', 'Page 86 of 110']\n\n###\n\n", "completion": "END"}